This study examined the synergetic effect of class IA
Phosphoinositide 3-kinases catalytic subunit p110β knockdown in conjunction with
oxaliplatin treatment on
colon cancer cells. Down-regulation of p110β by
siRNA interference and
oxaliplatin treatment were applied in
colon cancer cell lines HT29, SW620 and HCT116. MTT assay was used to measure the inhibitory effect of p110β knockdown on the proliferation of
colon cancer cell lines. SubG1 assay and
Annexin-V FITC/PI double-labeling cytometry were applied to detect cell apoptosis. And cell cycle was evaluated by using PI staining and flow cytometry. The expression of
caspase 3, cleaved PARP, p-Akt, T-Akt and p110β was determined by western blotting. The results suggested that down-regulation of p110β expression by
siRNA obviously reduced cell number via accumulation in G(0)-G(1) phase of the cell cycle in the absence of notablely increased apoptosis in
colon cancer cell lines HT29 and SW620 (S phase arrest in HCT116). Moreover, inhibition of p110β expression increased
oxaliplatin-induced cell apoptosis and cell cycle arrest in HT29, HCT116 and SW620 cell lines. In addition, increases of cleaved
caspase-3 and cleaved PARP induced by
oxaliplatin treatment were determined by immunoblotting in p110β knockdown group compared with normal control group and wild-type group. It is concluded that down-regulated expression of p110β could inhibit
colon cancer cells proliferation and result in increased chemosensitivity of
colorectal cancer cells to
oxaliplatin through augmentation of
oxaliplatin-induced cell apoptosis and cell cycle arrest.